+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years - 100Years
All Genders
ID07748988

Pilot Study Evaluating Casdatifan on Gene Expression in Refractory Metastatic Clear Cell Renal Cell Carcinoma

Led by Vanderbilt-Ingram Cancer Center · Updated on 2026-09-25

12

Participants Needed

1

Research Sites

26 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying the effects of casdatifan, an oral selective HIF-2 inhibitor, in patients with metastatic clear cell renal cell carcinoma ccRCC that has not responded to previous immune oncology and VEGF-targeted treatments. This phase I trial aims to evaluate how casdatifan influences specific genes associated with kidney cancer growth and to explore gene expression changes related to treatment response in this difficult-to-treat cancer. Participants take casdatifan orally at a fixed dose of 100 mg once daily on a continuous 28-day cycle, repeating cycles unless the disease worsens or side effects become unacceptable. Dose reductions to 50 mg or 25 mg once daily are permitted if needed due to side effects. Throughout the study, patients undergo CT or MRI scans, tumor biopsies, and blood sample collections to monitor changes. After stopping treatment for reasons other than disease progression, patients are followed every 12 weeks. During the trial, participants have regular imaging and biopsies to assess tumor gene expression and response to therapy. The primary outcome measures changes in HIF2-regulated genes within metastatic tumor tissue over one year. Secondary outcomes evaluate global tumor gene expression and differences between responders and non-responders. Safety monitoring and follow-up visits continue after treatment ends, with total participation lasting up to several years.

CONDITIONS

Brief Title

Casdatifan for the Treatment of Refractory Metastatic Clear Cell Renal Cell Carcinoma

Research Team

V

Vanderbilt-Ingram Services for Timely Access

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here